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The primary reservoir for hepatitis C virus (HCV) replication is believed to be hepatocytes, which are highly
polarized with tight junctions (TJ) separating their basolateral and apical domains. HepG2 cells develop
polarity over time, resulting in the formation and remodeling of bile canalicular (BC) structures. HepG2 cells
expressing CD81 provide a model system to study the effects of hepatic polarity on HCV infection. We found
an inverse association between HepG2-CD81 polarization and HCV pseudoparticle entry. As HepG2 cells
polarize, discrete pools of claudin-1 (CLDN1) at the TJ and basal/lateral membranes develop, consistent with
the pattern of receptor staining observed in liver tissue. The TJ and nonjunctional pools of CLDN1 show an
altered association with CD81 and localization in response to the PKA antagonist Rp-8-Br-cyclic AMPs
(cAMPs). Rp-8-Br-cAMPs reduced CLDN1 expression at the basal membrane and inhibited HCV infection,
supporting a model where the nonjunctional pools of CLDN1 have a role in HCV entry. Treatment of HepG2
cells with proinflammatory cytokines, tumor necrosis factor alpha and gamma interferon, perturbed TJ
integrity but had minimal effect(s) on cellular polarity and HCV infection, suggesting that TJ integrity does not
limit HCV entry into polarized HepG2 cells. In contrast, activation of PKC with phorbol ester reduced TJ
integrity, ablated HepG2 polarity, and stimulated HCV entry. Overall, these data show that complex hepato-
cyte-like polarity alters CLDN1 localization and limits HCV entry, suggesting that agents which disrupt
hepatocyte polarity may promote HCV infection and transmission within the liver.
Hepatitis C virus (HCV) poses a global health problem, with
over 170 million infected individuals worldwide. The principal
reservoir for HCV replication is believed to be hepatocytes in
the liver. Innate and adaptive cellular immune responses are
thought to play a critical role in controlling HCV replication.
However, in the majority of cases, the virus persists and the
resulting hepatitis leads to progressive liver injury, frequently
culminating in fibrosis and hepatocellular carcinoma. At the
present time there is no vaccine and the only established treat-
ment is alpha interferon (IFN-") in combination with ribavirin,
which is only partially effective. Hence, there is an urgent need
for the development of more effective therapies.
The recent discovery that some strains of HCV can replicate
in cell culture (HCVcc) and release infectious particles has
allowed the complete viral life cycle to be studied (30, 52, 58).
HCV initiates infection by attaching to molecules or receptors
at the cell surface, and current evidence suggests that the
tetraspanin CD81 (3, 10, 20, 26), scavenger receptor class B
member I (SR-BI) (2, 22, 48), and the tight junction (TJ)
proteins claudin-1 (CLDN1) and occludin (OCLN) (15, 37, 43,
55, 57) are required for HCV entry (reviewed in reference 50).
However, the exact role(s) played by each of the receptors is
unclear.
Many tissues in the body contain polarized cells, and hepa-
tocytes are known to be highly polarized, with TJs regulating
the paracellular transit of solutes. TJs comprise multiple trans-
membrane (CLDNs, OCLN, and the junctional adhesion mol-
ecule [JAM]), scaffolding, and signaling proteins (reviewed in
reference 40). CLDNs belong to a large family of transmem-
brane proteins that oligomerize and form TJ strands that en-
circle the apical region of the cell. In addition, CLDNs can act
as adhesion molecules, forming homodimeric and het-
erodimeric associations between adjacent cells (42), raising
questions with respect to their accessibility to HCV particles
and their role in the virus internalization process. To address
the role of polarization in HCV entry, we previously utilized
the well-characterized colorectal adenocarcinoma Caco-2 cell
line and demonstrated that disrupting epithelial barrier forma-
tion increased HCV entry, suggesting that TJs impose a phys-
ical barrier and restrict viral access to receptors (36).
Most epithelial cells, including Caco-2, exhibit a simple po-
larity consisting of single apical and basal surfaces that oppose
each other, with lateral surfaces participating in cell-cell asso-
ciations. In vitro studies commonly use cell monolayers grown
on semipermeable membranes, providing access to both
the apical and basolateral domains. However, hepatocytes in
the liver are polygonal and multipolar and do not possess the
columnar morphology of simple epithelial cells, with at least
two basal surfaces facing the circulation and a branched net-
work of grooves between adjacent cells constituting the apical
or bile canalicular (BC) surface. Thus, simple epithelial cell
systems may fail to recapitulate the more complex hepatic
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polarity that HCV will encounter in the liver. The majority of
immortalized hepatocyte-derived cell lines and primary hepa-
tocytes dedifferentiate in culture and fail to demonstrate a
complex polarized phenotype. However, several studies have
reported that the human HepG2 hepatoblastoma line develops
hepatic polarity in culture, forming apical cysts that are equiv-
alent to BC in the liver (reviewed in reference 13). Thus, we
have utilized the HepG2 cell line to investigate the effect(s) of
polarity on HCV infection.
Our studies demonstrate that HepG2 cells develop function-
ally active TJs and complex hepatic polarity that limit HCV
entry. As HepG2 cells polarize, discrete pools of CLDN1 at the
TJ and basal/lateral membranes develop, consistent with the
pattern of receptor staining noted for liver tissue. The TJ and
nonjunctional pools of CLDN1 show an altered association
with CD81 and localization in response to the protein kinase A
(PKA) antagonist (Rp-8-Br-cyclic AMPs [cAMPs]). The ob-
servation that Rp-8-Br-cAMPs reduce CLDN1 expression at
the basal membrane and inhibit HCV infection supports a
model where the nonjunctional pools of CLDN1 have a role in
HCV entry. Treatment of HepG2 cells with proinflammatory
cytokines, TNF-" and IFN-#, perturbed TJ integrity but had
minimal effect(s) on cellular polarity and HCV infection, sug-
gesting that the integrity of TJs does not restrict HCV entry
into polarized HepG2 cells. In contrast, activation of PKC with
phorbol ester reduced TJ integrity, ablated HepG2 polarity,
and stimulated HCV entry. Overall, these data show that com-
plex polarity limits HCV entry, suggesting that agents which
disrupt hepatocyte polarity may promote HCV infection and
transmission within the liver.
MATERIALS AND METHODS
Cell lines and antibodies. HepG2, Huh-7, and Huh-7.5 cells were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum and 1% nonessential amino acids at 37°C and 5% CO2. Primary
human hepatocytes (PHH) were isolated and cultured as previously reported
(41). HepG2 cells with aberrant E-cadherin distribution that lack functional
adherens junctions (HepG2 AJ$) were developed as previously reported (51)
and cultured as described above in the presence of 1 mg/ml G-418 (Invitrogen,
United Kingdom). Huh-7 and Huh-7.5 cells were kindly provided by Tianyi
Wang (University of Pittsburgh, PA) and Charles Rice (Rockefeller University,
New York, NY), respectively. HepG2 and HepG2 AJ$ cells were seeded at 4 %
104 to 6 % 104 cells/cm2, and Huh-7 and Huh-7.5 cells were seeded at 1.5 % 104
to 3 % 104 cells/cm2 on plastic or glass coverslips, depending on the assay being
performed. HepG2 cells expressing CD81, DsRED.CD81, and AcGFP.CLDN1
were generated by lentiviral transduction as previously described (24).
The following primary antibodies were used: anti-multidrug-resistant pro-
tein 2 (MRP2) (M2 III-6; Abcam Cambridge, United Kingdom), anti-NS5A
9E10 (C. Rice, Rockefeller University, NY), anti-CD81 (2s131), anti-SRBI
(S. Shaw, Pfizer), anti-OCLN (Zymed, CA), anti-CLDN1 JAY.8 (Invitrogen,
CA), anti-CLDN1 1C5-D9 (Novus, CO), and anti-ZO-1 (Zymed, CA). The
following secondary-labeled antibodies were obtained from Invitrogen, CA:
Alexa Fluor 488 goat anti-mouse immunoglobulin G (IgG), Alexa Fluor 488
goat anti-rabbit IgG, Alexa Fluor 633 goat anti-mouse IgG, and Alexa Fluor
633 goat anti-rabbit IgG.
Cell polarity determination. HepG2 cells and PHH were grown on 13-mm-
diameter borosilicate glass coverslips (Fisher Scientific, United Kingdom) to the
time point required and fixed in 3% paraformaldehyde at room temperature for
30 min. Cells were stained with anti-MRP2 in 0.1% Triton (Sigma Aldrich,
United Kingdom), 0.5% bovine serum albumin (BSA) in phosphate-buffered
saline (PBS), and Alexa Fluor 488-conjugated goat anti-mouse. Cell nuclei were
visualized using 4&,6&-diamidino-2-phenylindole (DAPI; Invitrogen). The polarity
index was determined by counting the number of MRP2-positive apical struc-
tures per 100 nuclei by using a Nikon Eclipse TE2000-S fluorescence microscope.
Determination of TJ “barrier” and “fence” functions. To determine the func-
tionality of TJs and whether they restrict the paracellular diffusion of solutes
from the BC lumen to the basolateral medium (barrier function), HepG2 cells
were incubated with 5 'M 5-chloromethylfluorescein diacetate (CMFDA; In-
vitrogen) at 37°C for 10 min to allow internalization and translocation to the BC
lumen by MRP2. After washing with PBS extensively, the capacity of BC lumens
to retain CMFDA was analyzed using a fluorescence microscope.
To examine the fence function of TJs, HepG2 cells were cooled to 0°C with
ice-cold PBS and incubated with 4 'M N-(N-[6-[(7-nitrobenz-2-oxa-1,3-diazol-
4-yl)amino]caproyl])-sphingosylphosphorylcholine (C6-NBD-SM) for 30 min to
label the basolateral plasma membrane while preventing endocytosis. Cells were
inspected under a fluorescence microscope to assess whether the fluorescent
lipids had diffused from the basolateral surface to the BC surface membrane or
if they had remained at the basolateral plasma membrane, indicating an intact TJ
fence function.
HCVpp generation and infection. Pseudoviruses were generated by transfect-
ing 293T cells (American Type Culture Collection, Manassas, VA) with two
plasmids, one encoding a human immunodeficiency virus provirus expressing
luciferase and the other encoding HCV strain H77 E1E2 region, the murine
leukemia virus (MLV) envelope, or a no-envelope control as previously de-
scribed (26). Supernatants were harvested at 48 h posttransfection, clarified, and
filtered through a 0.45-'m membrane. Virus-containing medium was added to
target cells plated as described above and incubated for 8 h, and unbound virus
was removed and the medium replaced with DMEM containing 3% fetal bovine
serum. At 72 h postinfection, the medium was removed and cells were lysed with
cell lysis buffer (Promega, Madison, WI). Luciferase activity was assayed by the
addition of the luciferase substrate, and measurements were taken for 10 s in a
luminometer (Lumat LB 9507). Specific infectivity was calculated by subtracting
the mean no-envelope control pseudoparticle signal from the HCV pseudopar-
ticle (HCVpp) or MLVpp signals. Infectivity was presented relative to that of
untreated control cells; i.e., the mean luciferase value (relative light units [RLU])
of the replicate untreated cells was defined as 100%.
HCVcc generation and infection. Stocks of J6/JFH virus were generated as
previously described (30). Briefly, RNA was transcribed in vitro from full-length
genomes using the MEGAscript T7 kit (Ambion) and electroporated into Huh-
7.5 cells. Seventy-two and 96 h postelectroporation, supernatants were collected
and stored immediately at $80°C. Virus containing medium was added to target
cells plated as described above, and infected cells were detected by methanol
fixation and staining for NS5A with anti-NS5A MAb 9E10 and Alexa 488-
conjugated anti-mouse IgG. Infection was quantified by enumerating NS5A-
positive foci, and infectivity was defined as the number of focus-forming units/
milliliter. The infectious titer of early nonadapted J6/JFH for HepG2-CD81 cells
was reduced 724-fold compared to the more permissive Huh-7.5 cell line.
Pharmacological treatments and compounds. Cells were plated as described
above either on glass coverslips or cell culture plastic, depending on the assay
being undertaken. Cells were serum starved for 4 h and treated with the follow-
ing inhibitor and stimulator concentrations that were shown to be nontoxic (data
not shown): 10 'M forskolin (FK) in the presence of 500 'M 3-isobutyl-1-
methylxanthine (Sigma, United Kingdom), 10 ng/ml human oncostatin M (OSM;
Cell Concepts, Germany); 1 mM dibutyryl cAMP (dbcAMP; Calbiochem, United
Kingdom); 1 mM 8-(4-chlorophenylthio adenosine-3&, 5&-cyclic monophosphor-
othioate Rp-isomer (Rp-8-CPT-cAMPs; BioLog, Germany), and 8-bromoad-
enosine-3&, 5&-cyclic monophosphorothioate Rp-isomer (Rp-8-Br-cAMPs;
BioLog, Germany). The control used in these experiments was dimethyl sulfox-
ide (DMSO; Sigma, United Kingdom) at a 1:1,000 dilution. For the Rho kinase
inhibitor Y-27632 (Sigma, United Kingdom), cells were incubated with 2.5 'M
Y-27632 for 24 h. For treatment with cytokines, cells were exposed to 10 ng/ml
TNF-" (PeproTech, United Kingdom), 10 ng/ml IFN-# (PeproTech, United
Kingdom), 50 ng/ml of phorbol-12-myristate-13-acetate (PMA; Sigma, United
Kingdom), or control PBS for 24 h before experimentation.
Immunohistochemistry. Representative 3-'m sections were cut from paraffin-
embedded blocks of formalin-fixed tissue, placed onto charged slides, and incu-
bated for 1 h at 60°C. Sections were dewaxed and rehydrated, and endogenous
peroxidase was blocked with 0.3% hydrogen peroxide in distilled water. The
tissue was subjected to an agitated low-temperature epitope retrieval technique
as previously described (45). Sections were mounted onto a Shandon sequencer,
blocked in 2% casein, and incubated with saturating concentrations of monoclo-
nal antibodies (MAbs) specific for CD81 (2s131), CLDN1 (Zymed; Invitrogen),
and OCLN (Zymed; Invitrogen) or control-irrelevant IgG diluted in Tris-buff-
ered saline-0.1% Tween (TBS-Tween) for 1 h. After a TBS-Tween wash, sections
were incubated with an ImPress Universal anti-mouse IgG/anti-rabbit IgG per-
oxidase kit (Vector Labs). After being washed further with TBS-Tween, bound
antibodies were visualized by using ImPact DAB diluent and a chromogen kit
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(Vector Labs) and counterstained with hematoxylin. Images were obtained using
a Nikon Eclipse E400 microscope. Acetone-fixed frozen sections of normal tissue
were stained in a comparable manner to confirm the pattern of CD81, CLDN1,
and OCLN expression had not been altered during paraffin wax processing and
formalin fixation.
Confocal microscopy. HepG2 cells were grown on 13-mm-diameter borosili-
cate glass coverslips (Fisher Scientific, United Kingdom) and fixed in 3% para-
formaldehyde (for anti-CD81 2s131) or ice-cold methanol (for all other antibod-
ies). Cells were permeabilized for 30 min in 0.05% saponin and 0.5% BSA in PBS
and incubated with primary antibodies for 1 h at room temperature in PBS-
saponin-BSA. Cells were washed three times in PBS-saponin-BSA before addi-
tion of the appropriate Alexa 488-conjugated anti-species IgG diluted to 1:1,000
in PBS-saponin-BSA for 1 h at room temperature. Cells were washed three times
in PBS-saponin-BSA before being counterstained with DAPI (Invitrogen) in
PBS for 5 min. Coverslips were mounted on glass slides (ProLong Gold antifade;
Invitrogen) and viewed by laser-scanning confocal microscopy (LSCM) on a
Zeiss META head confocal microscope with a %63 water-immersion objective.
Quantification of AcGFP.CLDN1 and DsRED.CD81 expression and FRET asso-
ciation. HepG2 cells transduced to express AcGFP.CLDN1 and DsRED.CD81
were grown on 13-mm glass coverslips and fixed in ice-cold methanol, and the TJ
location was identified by costaining for OCLN or ZO-1. The cells were imaged
by LSCM, with the microscope settings optimized for each fluorescent protein to
obtain the highest signal-to-noise ratio. The intensity of AcGFP.CLDN1 and
DsRED.CD81 expression (arbitrary fluorescence units/pixel) at the plasma
membrane of nonpolarized cells and the basal and lateral membranes and TJs of
polarized cells provides 500 to 1,000 measurements per cell. The data from 10
cells were normalized, and the localized expression was calculated. For fluores-
cent resonance energy transfer (FRET) analysis, the gradual acceptor photo-
bleaching method of FRET was used, which entailed photobleaching the
DsRED fluorophore gradually over time while monitoring AcGFP fluorescent
intensity, as previously described (24). After background and cross-talk correc-
tion, any increase in AcGFP intensity following DsRED photobleaching is due to
FRET between the proteins, implying a distance of less than 10 nm. Each pixel
has an AcGFP and DsRED fluorescent intensity that may increase or decrease
following acceptor photobleaching. The percent FRET is defined as the number
of pixels that display FRET over the total number of pixels analyzed.
Statistical analysis. Results are expressed the mean ( 1 standard deviation of
the mean (SD), except where stated to the contrary. Statistical analyses were
performed using Student’s t test in Prism 4.0 (GraphPad, San Diego, CA), with
a P value of )0.05 being considered statistically significant.
RESULTS
Effect of polarization on HCV entry. We previously reported
that HepG2 cells transduced to express CD81 support HCVpp
infection, and we utilized these cells to study the effect(s) of
polarity on HCV entry. HepG2-CD81 cells formed an increasing
number of BC over time, with approximately 38 BC detected per
100 cells at 5 days postplating (Fig. 1A). Since at least two cells
participate in the formation of one BC, this corresponds to at
FIG. 1. Effect of HepG2 polarity on HCV entry. (A) HepG2 cells were grown for 1, 3, or 5 days, fixed in 3% paraformaldehyde, and stained
for the BC-expressed marker MRP2. The polarity index was assessed by quantifying the number of MRP2-positive BC per 100 cell nuclei for five
fields of view on three replicate coverslips. (B) The BC in polarized HepG2 cells were assessed for both “barrier” and “fence” functions. Cells were
incubated with either C6-NBD-SM, to measure fence function, or CMFDA, which measures barrier function. Restriction of C6-NBD-SM to the
basal plasma membrane and restriction of CMFDA to the BC indicate that polarized HepG2 cells have functional TJs. (C) HCVcc J6/JFH was
used to infect HepG2-CD81 cells at 1, 3, or 5 days postplating. Infected cells were visualized after 72 h (NS5A staining), and infectivity (focus
forming units/milliliter) was calculated. **, P ) 0.001; ***, P ) 0.0001 (t test). (D) HCVpp (white bars) and MLVpp (black bars) infection of
HepG2-CD81 cells at 1, 3, or 5 days postplating. Infectivity is expressed relative to HepG2 cells infected immediately after plating ( SD. **, P )
0.001 (t test). HCVpp infectivity values for HepG2-CD81 and HepG2 cells after 1 day of plating were 20,753 ( 1,060 RLU and 360 ( 12 RLU;
MLVpp infectivity values for HepG2-CD81 and HepG2 cells were 140,187 ( 483 RLU and 143,471 ( 517 RLU.
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least 76% of the cells developing an apical membrane. CD81
expression did not alter the ability of HepG2 cells to polarize
(data not shown). To test the functionality of TJs, we investigated
the retention of BC-localized CMFDA and basolateral mem-
brane-associated C6-NBD-SM lipids. Eighty percent of BC re-
tained CMFDA, and a similar percentage of cells maintained
basolateral localized C6-NBD-SM (Fig. 1B), demonstrating that
HepG2-CD81 cells develop “barrier” and “fence” TJ activities.
To study the effect(s) of polarization on HCVcc infection,
we monitored the ability of J6/JFH to infect HepG2-CD81
cells at 1, 3, and 5 days postplating. As the percentage of
polarized cells in the culture increased, the frequency of cells
supporting HCVcc infection declined (Fig. 1C). Due to the low
permissivity of HepG2 cells in supporting HCV RNA replica-
tion (12), experiments were performed at a low multiplicity of
infection (MOI; 0.01 to 0.05). To ascertain if the reduced
frequency of NS5A-expressing cells in the polarized cultures
was due to differences in the HCV glycoprotein-dependent
entry, we studied the ability of HCVpp and control MLVpp to
infect HepG2-CD81 cells seeded at various times. Polarization
limits HCVpp infection, whereas MLVpp infection was unaf-
fected, demonstrating that the HCV glycoprotein-dependent
entry is reduced in polarized HepG2 cells (Fig. 1D).
To ascertain whether PHH polarize and form BC structures,
the cells were stained for the apical markers MRP2 and CD26.
A low frequency of BC was observed in two independent donor
preparations, suggesting that less than 5% of hepatocytes were
polarized. These data are consistent with reports in the liter-
ature that cultured hepatocytes show limited evidence of BC
morphogenesis (reviewed in reference 13). Both PHH cultures
supported J6/JFH replication as judged by reverse transcrip-
tion-PCR determination of HCV RNA relative to a cellular
housekeeping gene (glyceraldehyde-3-phosphate dehydroge-
nase [GAPDH]) (36). At 48 h postinfection, differences be-
tween HCV and GAPDH amplification threshold values of 9.3
(PHH donor 1), 10.23 (PHH donor 2), and 8.74 (Huh-7.5 cells)
were obtained, demonstrating that PHH support HCV repli-
cation at levels comparable to those of Huh-7.5 cells.
Several reports have highlighted the importance of PKA in
regulating cell polarity and the trafficking of proteins and lipids
to polarized cell surfaces. The decreased susceptibility of
HepG2-CD81 cells to virus over time suggests that HCV is less
able to enter polarized cells; however, other parameters may
have been modulated during their time in culture. To indepen-
dently study the effect of polarization on viral entry, we exam-
ined the effect of PKA agonists and the interleukin-6 family
cytokine OSM on HCVpp entry. HepG2-CD81 cells (3 days
postplating) were treated for 1 h with FK, which activates
adenylyl cyclase and increases intracellular cAMP, exogenous
dbcAMP, or OSM and were assessed for BC formation and
susceptibility to HCVpp infection. All of the treatments pro-
moted HepG2-CD81 polarization and induced a significant
decrease in HCVpp entry with minimal effect(s) on MLVpp
infection (Fig. 2A to B). In contrast, the various agents had no
detectable effect on HCVpp infection of Huh-7 or Huh-7.5
cells (data not shown). To confirm that the effect(s) of
dbcAMP on HCVpp entry is not due to the toxic effects of free
butyrate, cells were treated with an increasing concentration(s)
of dbcAMP in the presence or absence of the selective PKA
holoenzyme antagonist, Rp-8-CPT-cAMPs. Treatment with
FIG. 2. PKA stimulation of HepG2 polarity reduces HCV entry.
(A) Polarized HepG2-CD81 cells grown for 3 days were treated with
serum-free DMEM for 4 h before being exposed to FK (10 'M),
dbcAMP (1 mM), OSM (10 ng/ml), or control (DMSO; 1:1,000) for
1 h. Cells were fixed, and their polarity indexes were measured.
(B) HCVpp (white bars) or MLVpp (black bars) infection of polarized
HepG2-CD81 cells (3-day culture) after treatment with FK (10 'M),
OSM (10 ng/ml), dbcAMP (1 mM), or control (DMSO; 1:1,000) for
1 h. Infectivity is expressed relative to control-treated cells ( SD. *,
P ) 0.01; **, P ) 0.001 (t test). (C) Polarity (gray bars) and HCVpp
(white bars) or MLVpp (black bars) infection of HepG2-CD81 cells
following treatment with control (DMSO; 1:1,000), dbcAMP (0.1, 0.5,
and 1 mM), or 1 mM dbcAMP and 1 mM Rp-8-CPT-cAMPs. Cells
were treated with compounds for 1 h, following a 4-h incubation in
serum-free DMEM. The polarity index was measured as previously
described (left y axis). HCVpp and MLVpp infection was assessed 72 h
after treatment, and data are shown as relative infectivity (right y axis)
calculated as a percentage of control cells ( SD. **, P ) 0.001 (t test).
HCVpp infectivity values for HepG2-CD81 and HepG2 cells were
23,350( 1,583 RLU and 447( 14 RLU; MLVpp infectivity values for
HepG2-CD81 and HepG2 cells were 165,200 ( 158 RLU and
115,300 ( 177 RLU.
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dbcAMP induced a dose-dependent increase in polarity and a
reduction in HCVpp entry that was ablated in the presence of
the PKA antagonist (Fig. 2C). In summary, these data show
that polarized HepG2 cells are less able to support HCV entry.
The mature hepatic phenotype observed in the adult liver
develops during embryogenesis from nonpolarized hepato-
blasts into clusters of cells that initially form isolated intercel-
lular BC cavities and later form a branched BC network span-
ning multiple cells (19, 25, 34). The molecular mechanisms
directing the conversion from simple to complex polarity and
the BC organization of the adult liver are poorly defined.
HepG2 cells develop complex polarity over time, with multiple
cells sharing a common BC structure (Fig. 3A), providing an in
vitro system to study HCV entry into polarized cells that may
be more representative of the adult liver. Culturing cells on a
predeposited extracellular matrix or inhibition of Rho kinase
promotes the development of complex polarity (25). HepG2-
CD81 cells were treated with the Rho kinase inhibitor (Y-
27632), and the number of cells sharing a BC and their per-
missivity to HCVpp infection was assessed. Inhibition of Rho
kinase led to a greater number of cells sharing a BC and a
decline in the number of BC involving only two or three cells
(Fig. 3B). The increased frequency of complex polarized cells
in the population was associated with a significant reduction in
HCVpp entry, with no detectable effect on MLVpp entry (Fig.
3C). In contrast, HCVpp or MLVpp infection of Huh-7 or
Huh-7.5 cells was not modulated by prior treatment with
Y-27632 (data not shown). HepG2 cells with aberrant E-cad-
herin distribution that lack functional adherens junctions
(HepG2 AJ$) fail to develop complex polarity in vitro (51).
Y-27632 treatment of HepG2-CD81 AJ$ cells had no effect on
the number of cells sharing a BC or HCVpp and MLVpp
infection (Fig. 3C). In summary, these data demonstrate that
complex polarity restricts HCV entry into HepG2 cells.
Effect(s) of polarization on HCV receptor localization. Since
polarization reduces the ability of HepG2 to support HCV
entry, we were interested to study the effects of polarization on
viral receptor localization. HCV receptor expression was as-
sessed in nonpolarized and polarized HepG2-CD81 cells by
LSCM. The TJ-associated proteins OCLN and ZO-1 were
visible in polarized cells as a discrete band surrounding the BC
structure, depending on the cellular orientation (Fig. 4A and
data not shown). In contrast, CD81 and SR-BI demonstrated
plasma membrane staining in nonpolarized HepG2-CD81
cells, with both coreceptors at apical/BC and basal and lateral
membranes upon polarization (Fig. 4A). In nonpolarized cells,
CLDN1 is expressed at the plasma membrane, and upon po-
larization the protein relocalizes to the TJ, with the staining
FIG. 3. Effect of complex HepG2 polarity on HCV entry. (A) Cells grown for 1, 3, or 5 days were stained to visualize BC, and the number of
cells sharing a BC was enumerated. (B) HepG2-CD81 cells (1 day postplating) were treated with control (DMSO; 1:1,000) or Rho kinase inhibitor
Y-27632 (2.5 'M) for 24 h. Cells were fixed, and the number of cells sharing a BC was counted. To investigate the effect of complex polarity on
HCV entry, HepG2-CD81 (C) and HepG2-CD81 AJ$ (D) cells (1 day postplating) were treated with the control or Y-27632 before being infected
with HCVpp (white bars) or MLVpp (black bars) for 8 h. Data are shown as relative infectivity calculated as a percentage of control cells ( SD,
where the mean infection value of the control cells is defined as 100%. *, P ) 0.01 (t test). HCVpp infectivity values for HepG2-CD81 and HepG2
cells were 35,410 ( 3,219 RLU and 104 ( 4 RLU; MLVpp infectivity values for HepG2-CD81 and HepG2 cells were 335,343 ( 5,888 RLU and
354,100 ( 6,474 RLU.
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intensity at the basal and lateral membranes decreasing (Fig.
4A). To ascertain whether our in vitro observations reflect
receptor localization in vivo, we stained nondiseased liver tis-
sue for CD81, SR-BI, CLDN1, and OCLN. Hepatocyte mem-
branes stained uniformly for CD81 and SR-BI, and CLDN1
showed a dominant staining pattern at the BC and a lower
staining intensity at basolateral membranes, whereas OCLN
was detected only at the BC structures (Fig. 4B). Comparable
staining patterns were observed with formalin-fixed and frozen
liver tissue. In summary, these experiments show concordant
CD81, SR-BI, CLDN1, and OCLN localization in polarized
HepG2 cells and liver tissue.
We previously reported that FRET occurred between
fluorescent-tagged versions of plasma membrane-expressed
CLDN1 and CD81 in 293T and Huh-7.5 hepatoma cells, con-
sistent with the formation of receptor complexes (24). To
quantify the effect(s) of polarization on CLDN1 and CD81
localization and FRET association, HepG2 cells were trans-
duced to express AcGFP.CLDN1 and DsRED.CD81. The pat-
tern of AcGFP.CLDN1 staining in polarized HepG2 cells was
comparable to that observed for endogenous CLDN1 (Fig.
5A). Transduced HepG2 cells were costained for OCLN to
identify TJ structures, and the fluorescent intensity of CLDN1
and CD81 at the basal and lateral membranes and the TJs
estimated. The level(s) of CLDN1 expressed at the basal and
lateral membranes of polarized cells was comparable to that
observed in nonpolarized cells (Fig. 5B). However, in the po-
larized cells, CLDN1 is more highly expressed at the TJs,
whereas CD81 is more uniformly expressed in polarized and
nonpolarized cells, with no elevated expression at the TJs (Fig.
5B). The percentage of FRET between basal membrane-ex-
pressed pools of AcGFP-CLDN1 and DsRed-CD81 in polar-
ized HepG2 cells and plasma membrane-expressed proteins in
nonpolarized cells was comparable (37.5%( 4.7% and 41%(
11.5%, respectively). In contrast, there was no detectable
FRET between CLDN1 and CD81 at the TJs, suggesting that
the conformation, density, or stoichiometry of either protein at
this location is not compatible with coreceptor association. On
the assumption that CLDN1-CD81 complexes are important
for HCV entry (24, 55), these data lend further support for a
role of nonjunctional pools of CLDN1 in HCV entry.
We previously reported that inhibiting PKA in Huh-7.5 cells
induced a reorganization of CLDN1 from the plasma mem-
brane to intracellular sites and inhibited HCV entry (16). To
ascertain whether TJ and nonjunctional pools of CLDN1 in
HepG2 cells are equally sensitive to the effect(s) of the PKA
antagonist, Rp-8-Br-cAMPs, HepG2 cells stably expressing
AcGFP.CLDN1 and DsRED.CD81 were treated for 1 h and
the receptor localization was quantified. Inhibiting PKA had
no detectable effect(s) on CD81 localization (data not shown),
whereas Rp-8-Br-cAMPs modulated CLDN1 localization,
leading to a loss in basal membrane expression and an increase
in lateral- and TJ-associated forms (Fig. 6A to B). The treat-
ment led to a fivefold reduction in CLDN1-CD81 FRET at the
basal membrane (control, 39% ( 5.7%; Rp-8-Br-cAMPs,
8% ( 7.9%) and a significant decline in HCVpp entry (Fig.
6C) but no detectable effect on polarity (Fig. 6D). Since there
was no detectable effect(s) of Rp-8-Br-cAMPs on CLDN1-
CD81 FRET at the lateral or TJ domain, we tentatively con-
clude that the levels of CLDN1 expression at the basal mem-
brane may limit HCV entry.
Cytokine modulation of HepG2 TJ integrity and HCV entry.
To investigate a role for TJs in restricting entry of HCV into
polarized HepG2 cells, we assessed the effect(s) of TNF-" and
FIG. 4. Localization of viral receptors in HepG2 cells and liver tissue. (A) HepG2-CD81 cells were seeded onto glass coverslips at a density
resulting in polarized and nonpolarized cells in the population. Cells were dual-stained with antibodies specific for CD81, SR-BI, CLDN1, and
OCLN and visualized by confocal microscopy. Bar, 10 'm. (B) Liver sections (3 'm) were cut from paraffin blocks of formalin-fixed tissue and
stained with mouse MAbs to CD81, SR-BI, CLDN1, and OCLN. Tissue morphology is shown by arrows, along with sinusoidal endothelium (SE),
hepatocytes (H), and cell surfaces (white arrows) on apical canaliculi (A) and basolateral membranes (B).
6216 MEE ET AL. J. VIROL.
 at UNIV OF BIRM
INGHAM
 on July 14, 2009 
jvi.asm
.org
Downloaded from
 
IFN-# on HepG2-CD81 TJ integrity, polarity, and HCV entry.
PKC activation is reported to mediate the disassembly of TJs
in a variety of experimental systems (reviewed in reference 23),
and we therefore treated cells with the PKC stimulator PMA.
Both TNF-" and IFN-# treatments reduced TJ integrity by
approximately 50% (Fig. 7A) with no significant effect on po-
larity (Fig. 7B) or HCVpp entry (Fig. 7C). Neither treatment
had a discernible effect on CLDN1, ZO-1, or OCLN localiza-
tion (data not shown). In contrast, PMA abrogated TJ integrity
and significantly reduced HepG2 polarity (Fig. 7A to B), with
reduced expression of CLDN1, ZO-1, and OCLN at the TJs
(data nor shown). PMA treatment of HepG2-CD81 enhanced
HCVpp and HCVcc infection, with minimal effect on MLVpp
entry (Fig. 7C and data not shown). Activation of PKC is likely
to have pleiotropic effects on the cell, and it is interesting to
note that PMA had no effect on HCVpp or MLVpp infection
of Huh-7 or Huh-7.5 cells (Fig. 7D). We conclude that TJ
integrity per se does not restrict HCV entry into polarized
HepG2 cells and that cytokine-induced changes in TJs had a
modest effect on HCV entry.
DISCUSSION
Polarity is characterized by a specific organization of plasma
membrane proteins and defines the shape and architecture of
a cell. Hepatocyte polarity requires the coordinated establish-
ment and maintenance of TJs and apical membrane domains
(6, 27, 56). We demonstrate that HepG2 polarization limits
HCV entry (Fig. 1) and that treating cells with PKA agonist(s),
OSM, and Rho kinase inhibitor Y-27632, which stimulate po-
larization via distinct modes of action (25), specifically reduce
HCVpp infection (Fig. 2 and 3). HepG2 develops BC-like
spaces that form elongated canalicular lumens spanning sev-
eral cells (Fig. 3A to B) (25), and the resistance of HepG2-
CD81 cells to HCVpp infection following Rho kinase inhibi-
tion suggests that membrane remodeling associated with
canalicular development restricts viral entry (Fig. 3C). In con-
trast, canalicular structures were infrequently detected in cul-
tured PHH ()5%), consistent with their rapid dedifferentia-
tion in culture (reviewed in reference 53). We and others have
reported that PHH support low-level HCVcc replication; how-
ever, it has been difficult to quantify the frequency of infected
cells within the population and to study the role of polarity in
HCV entry (reviewed in reference 17).
To ascertain whether the reduced permissivity of polarized
HepG2 cells to HCV infection was due to a reorganization of
the viral receptors, we imaged endogenous and fluorescent-
tagged versions of CD81 and CLDN1. Both receptors localized
to areas of cell-cell contact in nonpolarized cells, and the
majority of CLDN1 redistributed to TJs upon polarization
(Fig. 4 and 5). In contrast, ZO-1 and OCLN appeared to
localize exclusively to TJs surrounding the BC (Fig. 4 and 5).
CD81, SR-BI, CLDN1, and OCLN localization in polarized
HepG2 cells was comparable to that observed in healthy liver
FIG. 5. Effect(s) of HepG2 polarization on CD81 and CLDN1 localization. (A) HepG2 cells transduced to express AcGFP.CLDN1 and
DsRED.CD81 were seeded onto glass coverslips. The cells were fixed 1 day postplating, stained for TJs with an antibody to OCLN, and visualized
by confocal microscopy. Bars, 20 'm. (B) Quantification of plasma membrane-expressed pools of AcGFP.CLDN1 and DsRED.CD81. Shown are
scatter plots of AcGFP.CLDN1 and DsRED.CD81 fluorescent intensity/pixel/cell at plasma membrane locations in polarized and nonpolarized
cells. Intensity is presented as arbitrary fluorescence units (AFU).
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tissue (Fig. 4), providing support for the use of HepG2 cells as
a model system to study HCV entry into polarized hepatocytes.
TJs are dynamically regulated (49), and the major pool(s) of
OCLN and ZO-1 in the T84 epithelial cell line is reported to
reside in Triton X-100-insoluble raft-like membrane microdo-
mains (39). Similarly, in polarized HepG2 cells we found that
the basal and lateral pools of CLDN1 and JAM-A are Triton
X-100 soluble, whereas TJ-associated CLDN1 and JAM-A are
insoluble to detergent extraction (data not shown). The pres-
ence of TJ and nonjunctional pools of CLDNs in the liver is
consistent with earlier reports (44). We hypothesize that non-
junctional CLDN1 may be more accessible to interact with the
viral glycoproteins during entry. Earlier studies showing that
CLDN1 expression in nonpolarized human embryonal 293T
kidney cells allow HCVpp entry support a model where entry
is not dependent on the formation of functionally active TJs
(15, 24, 31, 55, 57). Indeed, the observation that CLDN1 lack-
ing the C-terminal region that is required for transport to the
TJs (46) confers viral entry into 293T cells (15, 24) lends
further support to a model where nonjunctional CLDN1 has a
role in HCV entry.
The expression levels of tagged CLDN1 and CD81 at the
basal and lateral membranes of polarized cells were compara-
ble to that of the plasma membrane of nonpolarized HepG2
(Fig. 5B). We (24) and others (11, 55) reported that CLDN1
and CD81 associate at the plasma membrane, suggesting that
these complexes play a role in HCV entry. We demonstrate
that FRET occurred between membrane-expressed pools of
CLDN1 and CD81 at comparable efficiencies in polarized and
nonpolarized HepG2 cells to those previously reported in
Huh-7 and 293T cells (24), suggesting that receptor complex
formation does not limit HCV infection of polarized cells.
Interestingly, there was no detectable FRET between TJ-asso-
ciated pools of CLDN1 and CD81, suggesting that the confor-
FIG. 6. Inhibition of PKA modulates basolateral pools of CLDN1 and HCV entry. (A) HepG2 cells transduced to express AcGFP.CLDN1 and
DsRED.CD81 were seeded onto glass coverslips, and after 4 h in serum-free DMEM, they were treated with DMSO (control; 1:1,000) or
Rp-8-Br-cAMPs (500 mM) for 1 h. Cells were visualized using confocal microscopy, and the CLDN1 localization was assessed. Bars, 20 'm.
(B) Reorganization of AcGFP.CLDN1 after a 1-h treatment with control or Rp-8-Br-cAMPs (500 mM). The percentages of CLDN1 at the basal
(black), lateral (white), and TJ (gray) locations were measured. (C) HCVpp (white bars) and MLVpp (black bars) infection of HepG2-CD81 cells
(3 days postplating), following treatment with the control (1:1,000) or Rp-8-Br-cAMPs (50, 100, or 500 mM) for 1 h. Relative infectivity was
calculated as a percentage of control cells( SD. **, P) 0.001 (t test). HCVpp infectivity values for HepG2-CD81 and HepG2 cells were 14,710(
1,683 RLU and 447 ( 14 RLU; MLVpp infectivity values for HepG2-CD81 and HepG2 cells were 193,003 ( 1,873 RLU and 115,300 ( 1,140
RLU. (D) HepG2-CD81 cells were allowed to polarize over 3 days and were treated with serum-free DMEM for 4 h, followed by exposure to
control (1:1,000) or Rp-8-Br-cAMPs (50, 100, or 500 mM) for 1 h. Cells were fixed, and the polarity index was enumerated from five fields of view
from three independent coverslips.
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mation, density, or stoichiometry of the proteins at the TJ is
not compatible with coreceptor association. These data are
consistent with an earlier report by Kovalenko and colleagues,
who demonstrated an association between CLDN1 and the
tetraspanin proteins CD81 and CD9 in nonpolarized A431 and
A549 epithelial cells (29), leading them to suggest that tet-
raspanin-enriched microdomains regulate the trafficking of
nonjunctional CLDNs (reviewed in reference 21).
We recently demonstrated PKA-dependent localization of
CLDN1 in Huh-7 cells, such that inhibiting PKAII reduced
CLDN1 membrane expression and abrogated HCV entry (16).
To ascertain whether PKA regulates CLDN1 localization at
basal and lateral membranes and at TJ domains, HepG2 cells
expressing AcGFP.CLDN1 and DsRED.CD81 were treated
with the PKA antagonist, Rp-8-Br-cAMPs. Treatment reduced
CLDN1 expression at the basal membrane and increased lat-
eral- and TJ-associated forms with no detectable effect on
CD81 localization (Fig. 6B). The reduced CLDN1 expression
at the basal membrane abrogated FRET association with
CD81 at this site. Importantly, Rp-8-Br-cAMPs treatment in-
duced a significant reduction in HCVpp entry. One conse-
quence of HepG2 polarization in vitro, in particular the devel-
opment of multicellular structures with cells sharing a BC, is
the reduced availability of the basal membrane. Quantification
of the relative amount of basal and lateral membranes and TJ
domains in polarized HepG2 cells demonstrates that as more
cells share a BC, the TJ and basal surfaces reduce and the area
of lateral membrane increases, supporting the model that basal
membrane-expressed pools of receptors have a role in viral
entry.
Cytokine-mediated changes in cell permeability contribute
to a wide range of pathological conditions, including inflam-
matory bowel disease, cystic fibrosis, and perturbation of the
blood-brain barrier (reviewed in reference 8). While the mo-
lecular mechanisms regulating these processes are incom-
pletely understood, model cell culture systems of epithelial/
endothelial barrier function have highlighted the important
role of cytokines in regulating TJs. Treatment of HepG2-CD81
cells with TNF-" and IFN-# reduced TJ integrity and yet had
a minimal effect on cell polarization or HCVpp entry (Fig. 7).
TNF-" and IFN-# have been reported to modulate actin-
myosin contractility and to promote the endocytosis of TJ
proteins (reviewed in reference 8). However, the majority of
reports have utilized epithelial and endothelial cells with sim-
ple polarity, and the effect of cytokines on hepatic permeability
is poorly understood. Phorbol ester activation of PKC abro-
gated TJ integrity and significantly reduced HepG2 polarity,
with a concomitant increase in HCVpp infection (Fig. 7). PMA
induced a relocalization of CLDN1, ZO-1, and OCLN from
TJs, which was not apparent with either cytokine treatment
FIG. 7. Effect(s) of proinflammatory cytokines on HepG2 TJ integrity, polarity, and HCV entry. HepG2-CD81 cells were treated with the
control (DMSO; 1:1,000), TNF-" (10 ng/ml), IFN-# (10 ng/ml), or PMA (50 ng/ml) for 24 h. (A) Cells were incubated with CMFDA at 37°C for
10 min and washed, and the capacity of BC lumens to retain CMFDA was monitored by using fluorescence microscopy. TJ integrity was assessed
as the percentage of total BC retaining CMFDA (triplicate coverslips, five fields of view per coverslip). **, P ) 0.001 (t test). (B) Cells were fixed,
and the number of MRP2-positive BC per 100 cell nuclei was counted (polarity index). HCVpp (white bars) and MLVpp (black bars) infection
of control-, TNF-"-, IFN-#-, or PMA-treated HepG2-CD81 (C) or Huh-7.5 (D) cells is shown relative to control cells ( SD. ***, P ) 0.001 (t
test). HCVpp infectivity values for HepG2-CD81, HepG2, and Huh-7.5 cells were 48,350( 1,240 RLU, 313( 29 RLU, and 149,194( 9,869 RLU,
respectively. MLVpp infectivity values for HepG2-CD81, HepG2, and Huh-7.5 cells were 349,990 ( 7,075 RLU, 358,400 ( 18,162 RLU, and
727,454 ( 11,673 RLU, respectively.
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(data not shown). Several reports demonstrate that PMA ac-
tivation of PKC can signal a redistribution of TJ proteins from
the cell borders to the cytoplasm (9, 18, 38). The signaling
events downstream of PKC that regulate cell permeability are
incompletely defined; however, multiple components of the TJ
complex may be directly phosphorylated by PKC (reviewed in
reference 23). These data suggest that functionally intact TJs
per se do not limit HCV entry and highlight the differential
effect(s) of cytokine and PMA modulation of TJ integrity and
protein localization on HCV entry that is worthy of further
investigation.
The establishment and maintenance of a fully polarized state
requires the appropriate extracellular matrix, cell-cell contacts,
and correct geometrical orientation, with many epithelial cells
adopting a partially polarized morphology in monolayer cul-
ture. Huh-7 hepatoma and clonal derivatives such as Huh-7.5
(5) support high-level HCV RNA replication and are used
widely to study HCV infection and entry. We noted heteroge-
neous expression and localization of CLDN1, OCLN, and
JAM-A in Huh-7-derived hepatomas, with frequent breaks in
their lateral staining pattern(s). Furthermore, actin staining
was heterogeneous, with limited evidence for circumferential
bands colocalizing with ZO-1 and JAM-A (unpublished data),
as would be expected in a polarized monolayer (33, 35). All
treatments to regulate HepG2 polarity had minimal effects on
HCVpp or HCVcc infection of Huh-7 or Huh-7.5 cells, in
contrast to an earlier report demonstrating that TNF-" in-
duced a redistribution of CLDN1 from the plasma membrane
to intracellular sites in Huh-7.5.1 cells (55). Huh-7 cells are
heterogeneous with respect to morphology, CD81 expression,
and viral RNA replication, and this can change with in vitro
passage and culture conditions (1, 28, 32), making data com-
parison between laboratories difficult. Cumulatively, our data
suggest that Huh-7 cells fail to develop mature TJs, explaining
the relatively low transepithelial resistance values reported (4,
31) compared to those of more differentiated epithelial cell
lines. Recent reports of CLDN1 and OCLN colocalization with
ZO-1 at the apex of Huh-7 cells (7, 31) provide insufficient
evidence to demonstrate functional TJs, since both ZO-1 and
OCLN have been shown to be expressed in cells that lack TJs
(14, 47, 54). In contrast, HepG2 cells that develop and main-
tain complex polarity have been used extensively to define TJ
formation and regulation in the development of hepatic polar-
ity (reviewed in references 13 and 53). On the assumption that
HepG2 cells mimic hepatocyte polarity within the liver, our
data suggest that HCV entry may be suboptimal and that
agents which disrupt hepatocyte polarity may promote HCV
infection and transmission in the liver.
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